Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine.

Theranostics of nuclear medicine refers to the combination of radionuclide imaging and internal irradiation therapy, which is currently a research hotspot and an important direction for the future development of nuclear medicine. Radiopharmaceutical is a vital component of nuclear medicine and serves as one of the fundamental pillars of molecular imaging and precision medicine. At present, a variety of radiopharmaceuticals have been developed for various targets such as fibroblast activation protein (FAP), prostate-specific membrane antigen (PSMA), somatostatin receptor 2 (SSTR2), C-X-C motif chemokine receptor 4 (CXCR4), human epidermal growth factor-2 (HER2), and integrin αvβ, and some of them have been successfully applied in clinical practice.

High adsorption selectivity of ZnAl layered double hydroxides and the calcined materials toward phosphate.

The selective adsorption of phosphate ions was investigated on CO(3)(2-), Cl(-), and NO(3)(-)-type ZnAl layered double hydroxides (LDHs) and the calcined CO(3)(2-)-type LDH at 200, 400, 600 and 800 degrees C, respectively. The calcined LDHs and NO(3)(-)-type LDH showed high selectivity toward phosphate ions, while the Cl(-)-type LDH shows selectivity toward both SO(4)(2-) and phosphate ions. The NO(3)(-)-type LDH selectively adsorbed phosphate ions mainly through ion exchange.